Forxiga 10mg (Dapagliflozin)

Product Overview

Forxiga 10mg is a prescription oral medication that contains the active ingredient Dapagliflozin, a member of the sodium‑glucose cotransporter‑2 (SGLT2) inhibitor class. It is manufactured by AstraZeneca Pharma India Ltd, a globally recognized pharmaceutical company, and is specifically indicated for the treatment of type 2 diabetes mellitus in adults. The product is presented as a strip containing 14 tablets, each tablet delivering a strength of 10mg Dapagliflozin. In addition to the 14‑tablet strip, the medication is also available in pack sizes of 28, 56, and 84 tablets to accommodate longer treatment courses. Shipping times typically range from 6 to 15 days, depending on the destination, customs processing, and the selected delivery option.

What is Forxiga 10mg

Forxiga is the branded formulation of Dapagliflozin, a drug that works by selectively inhibiting the SGLT2 protein in the proximal renal tubules of the kidneys. This inhibition reduces the reabsorption of glucose, leading to increased urinary excretion of glucose and a consequent lowering of blood glucose concentrations. The medication received regulatory approval from authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), confirming its safety and efficacy for the intended indication. It is marketed under the name Forxiga and is supplied in a tablet form that is taken once daily, with or without food.

For a comprehensive scientific overview, you may refer to the PubMed study that details the pharmacodynamics of SGLT2 inhibition.

Uses and Benefits

Forxiga 10mg is primarily prescribed to improve glycemic control in adults with type 2 diabetes when diet and exercise alone are insufficient. Beyond glucose lowering, the drug offers several cardiovascular and renal benefits that have been documented in large outcome trials. These advantages make it a valuable option for patients who have or are at risk for cardiovascular disease.

• Improves hemoglobin A1c (HbA1c) by approximately 0.5% to 1.0% on average.
• Reduces the incidence of hyperglycemic emergencies, including diabetic ketoacidosis.
• Provides modest weight loss, typically 2–3 kg over six months.
• Helps lower systolic blood pressure by 3–5 mmHg.
• Decreases the risk of hospitalization for heart failure in patients with reduced ejection fraction.
• Offers renal protective effects, slowing the progression of chronic kidney disease.
• May reduce the need for additional antihyperglycemic agents such as insulin or sulfonylureas.

How It Works

The mechanism of action of Dapagliflozin involves blocking the SGLT2 transporter, which is responsible for reabsorbing filtered glucose back into the bloodstream. By preventing this reabsorption, the drug promotes the elimination of excess glucose through urine, resulting in a caloric loss that contributes to weight reduction. This process also leads to a modest reduction in intravascular volume and blood pressure, which can be beneficial for patients with hypertension or early heart failure. The drug’s half‑life is roughly 12–14 hours, supporting once‑daily dosing and maintaining steady plasma concentrations throughout the day.

For an in‑depth scientific explanation, see the peer‑reviewed review on SGLT2 inhibitors.

Dosage Guidelines

Forxiga is administered orally at a recommended starting dose of 10mg once daily for most adults with type 2 diabetes. If additional glycemic control is required, the dose may be titrated up to 20mg once daily, based on the clinician’s assessment and tolerability. In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 30–60 mL/min/1.73 m²), the maximum recommended dose remains 10mg daily. The medication should be taken at the same time each day to maintain consistent exposure.

If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular schedule resumed. Doubling the dose to compensate is not recommended. Patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) should not use Forxiga.

Regular monitoring of kidney function and electrolytes is advised, especially during the first few weeks of therapy, to identify any early signs of deterioration.

Side Effects

Like all pharmaceutical products, Forxiga 10mg may be associated with adverse effects. The most frequently reported side effects include genital mycotic infections, urinary tract infections, and increased urinary frequency. While most events are mild to moderate, clinicians should be aware of more serious potential complications.

• Hypoglycemia when combined with insulin or sulfonylureas.
• Acute kidney injury, particularly in patients with pre‑existing renal disease.
• Bone fracture risk, especially in post‑menopausal women.
• Necrotizing fasciitis of the perineum (Fournier’s gangrene), a rare but severe infection.
• Severe hypersensitivity reactions such as rash, angioedema, or anaphylaxis.

For a complete list of adverse events, consult the FDA prescribing information.

Warnings and Precautions

Prior to initiating therapy, healthcare professionals should assess renal function, cardiovascular status, and infection history. Forxiga is contraindicated in patients with a history of diabetic ketoacidosis related to type 1 diabetes or in those with severe renal impairment (eGFR <30 mL/min/1.73 m²). Adequate hydration is recommended to minimize the risk of volume depletion and related events.

Special populations, including pregnant or lactating women, should avoid use unless the expected benefit outweighs the potential risk, as determined by a qualified physician. Concomitant administration with other SGLT2 inhibitors or high‑dose diuretics may increase the likelihood of electrolyte imbalances. Patients should be counseled to report any signs of infection, especially genital or urinary, promptly.

Frequently Asked Questions

Question: Can Forxiga 10mg be used for type 1 diabetes?
Answer: No. Forxiga is approved only for type 2 diabetes mellitus and should not be used in patients with type 1 diabetes or in those experiencing diabetic ketoacidosis.

Question: How quickly does blood glucose improve after starting Forxiga?
Answer: Most patients observe a reduction in fasting glucose within 1–2 weeks, with measurable HbA1c improvements appearing after 12–24 weeks of consistent therapy.

Question: Will I lose weight while taking Forxiga?
Answer: Yes. Clinical studies have shown an average weight loss of 2–3 kg over six months, primarily due to increased urinary glucose excretion.

Question: What should I do if I develop recurrent urinary tract infections?
Answer: Contact your healthcare provider to evaluate the cause. Adjustments to dosage, counseling on hygiene, or alternative therapies may be recommended.

Question: Is Forxiga safe for patients with a history of heart failure?
Answer: Yes. Evidence from cardiovascular outcome trials indicates that Dapagliflozin reduces hospitalizations for heart failure in patients with reduced ejection fraction, but dosing should be individualized by a clinician.